Auris Medical Holding AG (NASDAQ:EARS)
Roth Capital Initiates Coverage On Auris Medical Holding AG (NASDAQ:EARS)’s stock to Buy with no specific Price Target. This rating was issued on 4/13/17. The stock recently closed its previous session at $0.85 by showing a percentage change of -27.35% from its previous day closing price of $1.17.
Price Target is basically a projection of future price of a company’s stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock.
Several investment firms issued their expert ratings on Auris Medical Holding AG (NASDAQ:EARS) in which Jefferies Maintains Auris Medical Holding AG (NASDAQ:EARS) to Buy by settling a price target of $8 on 3/15/16. Needham Initiates Coverage on the stock to Buy on 9/09/14 by stationing a price target of $11. JMP Securities Initiates Coverage on the company’s stock to Market Perform on 9/02/14 by setting a price target of $12. Jefferies Initiates Coverage on Auris Medical Holding AG (NASDAQ:EARS) to Buy with a price target of $12.
Auris Medical Holding AG (NASDAQ:EARS) currently has a consensus Price Target of $2.5. While some analysts have a High Price target for the stock of $2.5 and a Low Price Target of $2.5.
Several sell side analysts reviewed their recommendations on Auris Medical Holding AG (NASDAQ:EARS) where 0 analyst have rated the stock as Strong Buy, 1 analysts said it’s a Buy, 0 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell. (Current Month Yahoo Finance Ratings)
In the last Quarter, Auris Medical Holding AG (NASDAQ:EARS) reported its Actual EPS of $-1.4/share. The analysts offering Earnings Estimates for the company were believing that Auris Medical Holding AG (NASDAQ:EARS) could bring EPS of $-1.65/share. The difference between Actual EPS and Estimated EPS was 0.25 Percent. Thus the company showed an Earnings Surprise of 15.2 Percent.
Auris Medical Holding AG (NASDAQ:EARS) has a market capitalization of 20.46 Million. The stock traded with the volume of 13.44 Million shares in the last trading session. The stock touched its high share price of $9.50 on 11/27/17 and the stock also touched its Lowest price in the last 52-weeks of trading on 08/16/18 as $0.23. The company has a 1 Year high price target of $4. The stock is currently trading with a distance of 20-Day Simple Moving Average (SMA20) of 44.75%. The Moving Average SMA50 is 110.29% while SMA200 is -45.64%.
Auris Medical Holding AG (NASDAQ:EARS) is currently showing its ROA (Return on Assets) of -96.4%. The Return on Investment (ROI) is at 0% while it’s Return on Equity (ROE) value stands at 811.5%. The stock currently shows its YTD (Year to Date) performance of -85.61 percent while its Weekly performance value is 25%. The Monthly and Yearly performances are 195.14 percent and -89.24 percent respectively. The Relative Volume value measured for Auris Medical Holding AG (NASDAQ:EARS) is 2.46. The Average Volume (3 months) is 5.47 Million.
The stock currently has its Annual Dividend of $0 and an annual Dividend Yield of 0 Percent. EARS has P/E (Price to Earnings ttm) value of 0, Forward P/E of 0, P/C (Price to cash per share) of 0.81 and Price to Free Cash Flow (P/FCF) value of 0. The stock is showing its Operating Margin of 0 percent.
Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland.